BioRestorative TherapiesBRTX
BRTX
About: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Employees: 11
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.17% more ownership
Funds ownership: 3.9% [Q3] → 4.07% (+0.17%) [Q4]
0% more funds holding
Funds holding: 15 [Q3] → 15 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
14% less capital invested
Capital invested by funds: $468K [Q3] → $403K (-$64.5K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for BRTX.
Financial journalist opinion
Neutral
GlobeNewsWire
1 day ago
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date – – May also lead to Priority Review and Accelerated Biologics License Application (“BLA”) Approval for BRTX-100 – MELVILLE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to the BRTX-100 program for the treatment chronic lumbar disc disease (“cLDD”).
Neutral
GlobeNewsWire
2 months ago
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
– Covers cGMP manufacturing processes – – Expected to provide protection until April 29, 2040 – MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
Neutral
Seeking Alpha
3 months ago
BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief Executive Officer Francisco Silva – Vice President-Research and Development Conference Call Participants Jonathan Aschoff – ROTH Capital Michael Okunewitch – Maxim Group Elemer Piros – Rodman Operator Greetings. Welcome to the BioRestorative Third Quarter 2024 Results and New Additional Preliminary BRTX-100 Phase 2 Study Data Review Conference Call.
Neutral
GlobeNewsWire
3 months ago
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research –
Neutral
GlobeNewsWire
4 months ago
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Chief Executive Officer, Lance Alstodt, will participate in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024 in New York City.
Neutral
GlobeNewsWire
5 months ago
BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Chief Scientist and Vice President of Research and Development, Francisco Silva, will present at the 21st Annual International Federation for Adipose Therapeutics and Science (“IFATS”) Conference being held in Pittsburgh, PA from September 19-22, 2024.
Neutral
Seeking Alpha
6 months ago
BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:03 PM ET BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q2 2024 Earnings Conference Call August 13, 2024, 16:30 PM ET Company Participants Lance Alstodt - President, CEO and Chairman Robert Kristal - CFO Francisco Silva - VP, R&D Stephen Kilmer - Head of IR Conference Call Participants Jonathan Aschoff - ROTH MKM Michael Okunewitch - The Maxim Group Elemer Piros - Rodman and Renshaw Operator Good afternoon, and welcome to the BioRestorative Therapies Second Quarter 2024 Investor Call. At this time, all participants are in a listen-only mode and we will open for questions following the presentation.
Negative
Zacks Investment Research
6 months ago
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.77 per share a year ago.
Neutral
GlobeNewsWire
7 months ago
BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, is pleased to announce that its Chief Scientist and Vice President of Research and Development, Francisco Silva, has been named Section Editor of the newly launched Regenerative Medicine section of the Journal of Translational Medicine.
Neutral
GlobeNewsWire
7 months ago
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
– Adds to comprehensive patent portfolio underlying novel ThermoStem ® technology platform –
Charts implemented using Lightweight Charts™